Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F(2α)-III, an index of oxidant stress

American Journal of Respiratory and Critical Care Medicine

Volumn 158, Issue 6, 1998, Pages 1709-1714

  Praticò, Domenico ^b   Basili, Stefania ^b   Vieri, Marco ^b   Cordova, Corrado ^b   Violi, Francesco ^b   Fitzgerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ISOPROSTANE DERIVATIVE; ISOPROSTANE F2ALPHA 3; THROMBOXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG URINE LEVEL; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0032446729     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.158.6.9709066     Document Type: Article

References (39)

1. Slater, T. F. 1994. Free radical mechanism in tissue injury. Biochem. J. 222:1-15.
2. Repine, J. E., A. Bast, I. Lankhorst, and The Oxidative Stress Study Group. 1997. Oxidative stress in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 156:341-357.
3. Baldwin, S. R., R. H. Simon, C. M. Grum, L. A. Boxer, R. H. Simon, L. H. Ketai, and L. J. Devall. 1986. Oxidant activity in expired breath of patients with adult respiratory distress syndrome. Lancet 1:11-14.
4. Rahman, I., D. Morrison, K. Donaldson, and W. MacNee. 1996. Systemic oxidative stress in asthma, COPD, and smokers. Am. J. Respir. Cril. Care Med. 154:1055-1060.
5. Doelman, C. J. A., and A. Bast. 1990. Oxygen radicals in lung pathology. Free Radic. Biol. Med. 9:381-400.
6. American Thoracic Society. 1995. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. ATS Statement. Am. J. Respir. Crit. Care Med. 152(Suppl.):S77-S121.
7. Siafakas, N. M., P. Vermeire, N. B. Pride, P. Paoletti, J. Gibson, P. Howard, J. C. Yernault, M. DeCramer, T. Higgenbottom, D. S. Postma, and J. Rees. 1995. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): a consensus statement of the European Respiratory Society (ERS). Eur. Respir. J. 8:1398-1420.
8. Mohsenin, V. 1991. Lipid peroxidation and antielastase activity in the lung under oxidant stress: role of antioxidant defenses. J. Appl. Physiol. 70:1456-1462.
9. Pinamonti, S., M. Muzzuli, M. C. Chicca, A. Papi, F. Ravenna, L. M. Fabri, and A. Ciaccia. 1996. Xanthine oxidase activity in bronchoalveolar lavage fluid from patients with chronic obstructive lung disease. Free Radic. Biol. Med. 21:147-155.
10. DeKhuijzen, P. N. R., K. K. H. Aben, I. Dekker, L. P. H. J. Aarts, P. L. M. L. Wedlers, C. L. A. van Herwaarden, and A. Bast. 1996. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 154:813-816.
11. Gutteridge, J. M. C., and B. Halliwell. 1990. The measurement and mechanism of lipid peroxidation in biologic systems. Trends Biochem. Sci. 15:129-135.
12. 2α, is formed in vivo. Biochim. Biophys. Acta 1210:244-248.
13. 2α: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br. J. Clin. Pharmacol. 42:15-19.
14. 2α. J. Biol. Chem. 270:9800-9808.
15. Patrono, C., and G. A. FitzGerald. 1997. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler. Thromb. Vasc. Biol. 17:2309-2315.
16. Rokach, J., S. P. Khanapure, S.-W. Hwang, M. Adiyaman, J. A. Lawson, and G. A. FitzGerald. 1997. Nomenclature of isoprostanes: a proposal. Prostaglandins 54:853-873.
17. 2α generation during coronary reperfusion: a potential quantitative marker of oxidant stress in vivo. Circulation 95:2492-2499.
18. Reilly, M., N. Delanty, J. A. Lawson, and G. A. FitzGerald. 1996. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94:19-25.
19. Praticò, D., L. Iuliano, S. Basili, D. Ferro, C. Camastra, C. Cordova, G. A. FitzGerald, and F. Violi. 1998. Enhanced lipid peroxidation in hepatic cirrhosis. J. Investig. Med. 46:51-57.
20. 2α by human monocytes: discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J. Biol. Chem. 271: 8919-8924.
21. 2α-I: an index of lipid peroxidation in humans. Proc. Natl. Acad. Sci. U.S.A. 95:3449-3454.
22. 2α, in rabbit lung in situ. Am. J. Physiol. 263:H660-H663.
23. 2: an index of thromboxane formation in the human circulation. Proc. Natl. Acad. Sci. U.S.A. 83:5861-5865.
24. Gutteridge, J. M. C. 1986. Aspects to consider when detecting and measuring lipid peroxidation. Free Radic. Res. Common. 1:173-184.
25. Reaven, P. D., and J. L. Witztum. 1993. Comparison of supplementation of RRR-α-tocopherol and racemic α-tocopherol in humans: effects on lipid levels and lipoprotein susceptibility to oxidation. Arterioscler. Thromb. 13:601-608.
26. 2α, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro. Am. J. Respir. Crit. Care Med. 153:590-596.
27. 2α in the airways of human subjects. Am. J. Respir. Cell Mol. Biol. 9:568-572.
28. Rahman, I., E. Skwarska, and W. MacNee. 1997. Attenuation of oxidant/ antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease. Thorax 52:565-568.
29. Postma, D. S., T. E. J. Renkema, J. A. Noordhoek, H. Faber, H. J. Sluiter, and H. Kauffman. 1988. Association between nonspecific bronchial hyperreactivity and superoxide anion production by polymorphonuclear leukocytes in chronic airflow obstruction. Am. Rev. Respir. Dis. 137:57-61.
30. Lehr, H.-A., A. S. Weyrich, R. K. Saetzler, A. Jurek, K. E. Arfors, G. A. Zimmerman, S. M. Prescott, and T. M. McIntyre. 1997. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J. Clin. Invest. 99:1-7.
31. McAdam, B. F., and G. A. FitzGerald. 1996. Enzymatic regulation of the prostaglandin response in a human model of inflamamtion. In N. Bazan, J. Botting, and J. Vane, editors. New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules. Kluwer Academic Publishers, London. 117-123.
32. Nowak, J., J. J. Murray, J. A. Oates, and G. A. FitzGerald. 1987. Biochemical evidence of a chronic abnormality in platelet and vascular function in apparently healthy chronic cigarette smokers. Circulation 76:6-14.
33. Christman, B. W., C. D. McPherson, J. H. Newman, G. A. King, G. R. Bernard, B. M. Groves, and J. E. Loyd. 1992. An imbalance between the excretion of thromboxane and prostaclycin metabolites in pulmonary hypertension. N. Engl. J. Med. 327:70-75.
34. 2-isoprostanes) in smokers. N. Engl. J. Med. 332:1198-1203.
35. Schrauftatter, I. V., S. D. Revak, and C. G. Cochran. 1984. Proteases and oxidants in experimental pulmonary inflammatory injury. J. Clin. Invest. 73:1175-1184.
36. Morrison, H. M., J. A. Kramps, D. Burnett, and R. A. Stockley. 1987. Lung lavage fluid from patients with α-1-proteinase inhibitor deficiency or chronic obstructive bronchitis: antielastase function and cell profile. Clin. Sci. 72:373-381.
37. Liuzzo, G., B. Gallimore, R. L. Grillo, A. G. Rebuzzi, M. B. Pepys, and A. Maseri. 1997. Prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 336:973-979.
38. Jousilahti, P., E. Vartiainen, E. J. Tuomilethto, and P. Puska. 1996. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 348: 567-572.
39. 2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100: 2028-2034.